Cargando…
Aspects of innate immunity in Sjögren's syndrome
Previously, a dominant role of the adaptive immune system in the pathogenesis of Sjögren's syndrome was suspected. Recent advances, however, have revealed a major role of the type I IFN pathway, documented by an increased circulating type I IFN activity and an IFN 'signature' in perip...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218872/ https://www.ncbi.nlm.nih.gov/pubmed/21635716 http://dx.doi.org/10.1186/ar3318 |
_version_ | 1782216746851106816 |
---|---|
author | Low, Hui Zhi Witte, Torsten |
author_facet | Low, Hui Zhi Witte, Torsten |
author_sort | Low, Hui Zhi |
collection | PubMed |
description | Previously, a dominant role of the adaptive immune system in the pathogenesis of Sjögren's syndrome was suspected. Recent advances, however, have revealed a major role of the type I IFN pathway, documented by an increased circulating type I IFN activity and an IFN 'signature' in peripheral blood mononuclear cells and minor salivary gland biopsies from the patients. Polymorphisms in the genes IRF5 and STAT4 leading to increased IFN activation are associated with disease susceptibility. In the pathogenesis of Sjögren's syndrome, the activation of salivary gland epithelial cells appears to be the initial event. Once intrinsically activated, they express costimulatory and Toll-like receptors (TLRs) and MHC class I and II molecules, can present autoantigens and produce proinflammatory cytokines. The subsequent activation of plasmacytoid dendritic cells induces the production of high levels of proinflammatory cytokines in individuals with the risk alleles of the susceptibility genes IRF5 and STAT4. Under the influence of the high IFN concentration in the glands and through TLR ligation, B-cell activating factor is produced by epithelial cells and, together with autoantigen presentation on salivary gland epithelial cells, stimulates the adaptive immune system. In view of the central role of IFNalpha in at least the initiation of the pathogenesis of Sjögren's syndrome, blockade of this cytokine may be a rational therapeutic approach. |
format | Online Article Text |
id | pubmed-3218872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32188722011-11-27 Aspects of innate immunity in Sjögren's syndrome Low, Hui Zhi Witte, Torsten Arthritis Res Ther Review Previously, a dominant role of the adaptive immune system in the pathogenesis of Sjögren's syndrome was suspected. Recent advances, however, have revealed a major role of the type I IFN pathway, documented by an increased circulating type I IFN activity and an IFN 'signature' in peripheral blood mononuclear cells and minor salivary gland biopsies from the patients. Polymorphisms in the genes IRF5 and STAT4 leading to increased IFN activation are associated with disease susceptibility. In the pathogenesis of Sjögren's syndrome, the activation of salivary gland epithelial cells appears to be the initial event. Once intrinsically activated, they express costimulatory and Toll-like receptors (TLRs) and MHC class I and II molecules, can present autoantigens and produce proinflammatory cytokines. The subsequent activation of plasmacytoid dendritic cells induces the production of high levels of proinflammatory cytokines in individuals with the risk alleles of the susceptibility genes IRF5 and STAT4. Under the influence of the high IFN concentration in the glands and through TLR ligation, B-cell activating factor is produced by epithelial cells and, together with autoantigen presentation on salivary gland epithelial cells, stimulates the adaptive immune system. In view of the central role of IFNalpha in at least the initiation of the pathogenesis of Sjögren's syndrome, blockade of this cytokine may be a rational therapeutic approach. BioMed Central 2011 2011-05-27 /pmc/articles/PMC3218872/ /pubmed/21635716 http://dx.doi.org/10.1186/ar3318 Text en Copyright ©2011 BioMed Central Ltd |
spellingShingle | Review Low, Hui Zhi Witte, Torsten Aspects of innate immunity in Sjögren's syndrome |
title | Aspects of innate immunity in Sjögren's syndrome |
title_full | Aspects of innate immunity in Sjögren's syndrome |
title_fullStr | Aspects of innate immunity in Sjögren's syndrome |
title_full_unstemmed | Aspects of innate immunity in Sjögren's syndrome |
title_short | Aspects of innate immunity in Sjögren's syndrome |
title_sort | aspects of innate immunity in sjögren's syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218872/ https://www.ncbi.nlm.nih.gov/pubmed/21635716 http://dx.doi.org/10.1186/ar3318 |
work_keys_str_mv | AT lowhuizhi aspectsofinnateimmunityinsjogrenssyndrome AT wittetorsten aspectsofinnateimmunityinsjogrenssyndrome |